The polyglutamine ( polyQ) diseases consist of nine neurodegenerative diseases in which a polyQ tract expansion leads to protein misfolding and subsequent aggregation. Even when the causative proteins have the same length polyQ tract, there are differences in the severity and age of disease onset which implicate the polyQ flanking sequences as modulators of disease. Recent studies on the polyQ proteins ataxin-1, ataxin-3 and huntingtin exon-1 have shown that the flanking domains have an intrinsic ability to aggregate. This complex behavior leads to a multi-stage aggregation mechanism which we have termed multi-domain misfolding. In multi-domain misfolding, a flanking domain to the polyQ tract plays an early role in aggregation, before the contribution of the polyQ tract. A number of factors including the stability, dynamics and amyloidogenicity of the flanking domain modulate the impact on polyQ tract aggregation as well as any protein -protein interactions it undertakes. In this review, we examine the recent data in support of this novel mechanism of protein aggregation.
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PolyQ aggregation and protein context
The polyglutamine ( polyQ) diseases are a group of nine inherited diseases (Table I ) whereby mutation, in the form of a CAG repeat expansion, results in neurodegenerative disease. An inverse exponential correlation exists between glutamine repeat length and age of disease onset and severity (Gusella and MacDonald, 2000) . The same polyQ expansion in different contexts results in varying toxicity and disease pathology, and thus many studies have investigated the role that protein context plays in modulating the extrinsic toxicity of the polyQ sequence. Recently, the flanking domains of three polyQ proteins ataxin-1, ataxin-3 and huntingtin ( Fig. 1 ) have been shown, in vitro, to have intrinsic aggregation propensities which modulate the aggregation of the full-length proteins. In this review, we will focus on the aggregation of these proteins and discuss multi-domain misfolding events which result in their multi-stage aggregation mechanisms.
The ability of polyQ flanking sequences to modulate aggregation was clearly demonstrated by Nozaki et al. (2001) who saw differing aggregation rates when the surrounding 17 amino acids of ataxin-2, ataxin-3, huntingtin and atrophin were added to the same length polyQ tract. In addition to this, they found that mutating four hydrophobic residues in the upstream flanking sequence of ataxin-2 to charged amino acids decreased the aggregation rate, further highlighting the impact of sequence specificity upon aggregation.
Subsequently, a number of studies have investigated the flanking regions to the polyQ tract within huntingtin exon-1. Through the use of peptide studies, the poly proline ( polyP) region immediately C-terminal to the polyQ tract in huntingtin ( Fig. 1 ) has been shown to slow aggregation and decrease the stability of aggregates compared with a polyQ peptide alone (Bhattacharyya et al., 2006) . This study also found that the protective effects of the polyP region are directional, having no impact on aggregation when N-terminal to the polyQ tract. The mechanism of inhibition was investigated by Darnell et al. (2007) who show that the polyP region exists as a PPII helix ( proline type II helix), inducing a PPII-like structure in the polyQ tract that opposed the aggregation-prone b-sheet conformation formed by this region. In addition to the in vitro study using polyQ peptides, it was shown that the polyP sequence decreases toxicity in a yeast huntingtin exon-1 model system (Duennwald et al., 2006) . Duennwald et al. also investigated the impact of two commonly used tags and show that the soluble GST domain prevents toxicity whereas the negatively charged FLAG tag increases toxicity. Therefore, the polyQ surrounding sequence within huntingtin exon-1 has a significant modulating effect on huntingtin exon-1 aggregation kinetics.
The flanking domain also plays a role in determining the molecular species formed during aggregation (Fig. 2) . Although pathogenic length pure polyQ peptides only form two species during aggregation, monomer and fibril ( Fig. 2 ) (Chen et al., 2002) , in the context of the disease, protein intermediate species such as spherical oligomers and curvilinear protofibrils are also formed (Gales et al., 2005; Thakur et al., 2009 ). Similar to a number of other amyloidogenic proteins, polyQ oligomers have also been shown to be toxic (Bucciantini et al., 2002; Li et al., 2007; Takahashi et al., 2008) , showing the importance of flanking domains in controlling the species formed during fibrillogenesis.
The sequence-specific effects of the flanking domain are unsurprising, given that primary protein sequences vary in their amyloidogenicity. Aggregation is known to depend on factors determined by the primary sequence such as hydrophobicity, charge and propensity to form secondary structure (Chiti et al., 2003) , with certain amino acids having specific effects upon aggregation propensity. In keeping with its inhibitory effect on huntingtin exon-1 aggregation, proline is considered to be a 'b-breaker' as it is structurally incompatible with b-sheet formation (Monsellier and Chiti, 2007) . There is also a group of 'gatekeeper' residues which are commonly found flanking aggregation-prone regions. These include proline, lysine, arginine, glutamate and aspartate, and all have low hydrophobicity, are charged and show a low propensity to form b-sheet structure (Rousseau et al., 2006) , as demonstrated in the mutagenesis study on ataxin-2 (Nozaki et al., 2001) .
Analysis of primary sequence can be very informative for unstructured proteins; however, for the natively structured polyQ proteins, an extra level of complexity exists. Evolution selects for burial of hydrophobic amyloidogenic regions, and so predicted amyloidogenic regions may be buried in a stable fold and shielded from forming the interactions required for aggregation. Thus, local destabilization of the native protein fold or increased dynamics is needed before aggregation can occur (Tartaglia et al., 2008) . The role of dynamics in the initial misfolding events of polyQ aggregation has not been well characterized. We speculate that as for a number of other amyloid proteins (Wu et al., 2008; Hodkinson et al., 2009) , the more dynamic the native state polyQ protein is, the more frequently it will sample amyloidogenic-prone conformations. The question remains as to whether mutation, such as the polyQ expansion in polyQ proteins, can change the protein dynamics and subsequently affect aggregation.
In addition to having a direct impact upon the polyQ tract, the flanking sequences allow for varying protein -protein interactions which also modulate aggregation. Ubiquitin is one protein present in the neuronal intranuclear inclusions (NIIs) of most polyQ diseases; however, typically the subset DRPLA, dentatorubral and pallidoluysian atrophy; HD, Huntington's disease; SCA, spinocerebellar ataxia; SBMA, spinal and bulbar muscular atrophy; CACNA1A-alpha. 1A-voltage-dependent calcium channel; TBP, TATA-box-binding protein. H.M.Saunders and S.P.Bottomley of proteins sequestered within the NIIs is specific to each disease. The importance of the flanking domain in determining interactions is seen in ataxin-3, where differences between components of NIIs have been shown between full length versus truncated ataxin-3 (Chai et al., 2001) . In addition to this, huntingtin has over 100 interaction partners within the cell, all of which could potentially affect aggregation (Kaltenbach et al., 2007) . Therefore, flanking sequences and domains, although not the key cause of toxicity in polyQ proteins, can have a modifying effect on polyQ aggregation through their interactions partners.
Characterization of multi-domain misfolding and aggregation
It has long been known that protein domains can fold independently, and recently, it has been shown that within a protein, multiple domains are able to misfold in separate steps. Owing to the technical difficulties involved in producing these proteins in vitro, the aggregation kinetics and pathways of only three of the nine polyQ proteins have been characterized. Ataxin-1, ataxin-3 and huntingtin exon-1 all contain a flanking region which is able to aggregate independently of the polyQ tract, albeit with slower kinetics. A key tool in the identification of these polyQ-independent aggregation regions has been the polyQ binding peptide QBP1, which inhibits aggregation by the polyQ tract (Nagai et al., 2000) . The ability of flanking regions to independently aggregate accounts for the aggregation seen by non-expanded ataxin-1 and ataxin-3 in vitro (Chow et al., 2004a; Masino et al., 2004; de Chiara et al., 2005a de Chiara et al., , 2005b Gales et al., 2005) .
The aggregation pathway of ataxin-3 has been well defined in vitro and it has been shown that the folded 24 kDa Josephin domain of ataxin-3 aggregates when isolated (Chow et al., 2004c; Masino et al., 2004) . Our group has shown that full-length ataxin-3 aggregates with a two-stage mechanism (Ellisdon et al., 2006 (Ellisdon et al., , 2007 . The first stage of aggregation involving interactions of the Josephin domain results in formation of morphologically similar soluble protofibrils by ataxin-3 with any length glutamine tract. The key evidence these fibrils are formed along the same aggregation pathway is their ability to cross-seed each other (Ellisdon et al., 2006) . We know from the addition of QBP1 that the polyQ tract is not directly involved in the first step; however, the expanded ataxin-3 has the fastest aggregation kinetics, suggesting that it still impacts the Josephin domain in some way. The second stage in the polyQ aggregation mechanism involves a subsequent misfolding event, whereby interaction of the polyQ tract results in formation of SDS-insoluble fibrils. Thus, the two domains in ataxin-3, with an intrinsic ability to misfold, aggregate sequentially (Fig. 3) .
Although a complete kinetic analysis has not been completed for ataxin-1 due to the limitations caused by its size, the AXH domain of ataxin-1 has similarly been found to aggregate when isolated (de Chiara et al., 2005a (de Chiara et al., , 2005b . Within the context of ataxin-1, the AXH domain has a pro-aggregation effect, as replacement with a homologous non-aggregation-prone sequence decreases the formation of nuclear inclusions within a cell model (de Chiara et al., 2005a (de Chiara et al., , 2005b . The formation of detergent insoluble aggregates, commonly attributed to polyQ tract aggregation, has not been investigated, nor has the use of QBP1 to ascertain whether the polyQ tract misfolds and aggregates subsequently to the AXH domain.
A recent study by the Wetzel group has shown that huntingtin exon-1 also undergoes multi-domain misfolding during aggregation (Thakur et al., 2009) . They found the 17 amino acids N-terminal of the polyQ tract accelerated aggregation, whether N-or C-terminal to the polyQ tract. This differs from ataxin-1 and ataxin-3, in that the 17 amino acids are not a globular structured domain, but instead exists in a collapsed state, which an expanded polyQ tract induces into a more aggregation competent extended conformation.
Intriguingly, a kinetic analysis of the huntingtin peptide with the N-terminal sequence resulted in a critical nucleus of minus one, which suggests there is no kinetic barrier to aggregation, and spontaneous aggregation of oligomers occurs in a 'downhill' fashion (Thakur et al., 2009) . They also found that amorphous aggregates formed in the initial step of aggregation had an exposed polyQ tract that could still bind antibodies, whereas later aggregates masked the polyQ epitope, thus suggesting an additional misfolding event and conformational rearrangement of the polyQ tract to become involved in the fibrils (Thakur et al., 2009) . Thus, Fig. 3 . PolyQ multi-domain aggregation mechanism. This is a schematic representation of the multi-stage polyQ aggregation mechanism. In this pathway, an initial misfolding event occurs in the polyQ flanking folded domain (square), followed by the formation of soluble species mediated by flanking domain interactions. There is then a conformational rearrangement of the polyQ tract (orange) which results in formation of end stage SDS-insoluble fibrils. Multi-domain misfolding huntingtin exon-1 involves two different misfolding events which each result in formation of different species along the pathway.
With the presence of an amyloidogenic flanking domain being common to polyQ disease proteins, model polyQ protein containing flanking domains with an intrinsic ability to aggregate provide the most representative insight into the aggregation mechanism of polyQ proteins. One model polyQ system involving the cellular retinoic acid binding protein I (CRABP I) domain fused to huntingtin exon-1 has proved to have an aggregation pathway which is analogous to ataxin-3. The CRABP I domain has been demonstrated to aggregate independently and when fused to huntingtin exon-1, the aggregation pathway is characterized by an initial step involving CRABP I followed by a second step mediated by polyQ tract interactions (Ignatova et al., 2007) . Using proteolysis, this study also observed the two-stage aggregation pathway in an Escherichia coli cell model, which is the first evidence of the multi-domain mechanism within the cell. The recent huntingtin exon-1 aggregation study by the Wetzel group highlights the importance of detecting aggregation by a number of techniques in vitro, and thus it would be interesting to investigate whether the additional aggregation step due to the flanking 17 amino acids could also be identified within the context of the CRABP I model, with the possibility of three independently aggregating domains within the one protein.
Therefore, the three characterized polyQ proteins all show domain independent misfolding which translates into multi-step aggregation pathways, whereby the different domains aggregate sequentially. Common to all three cases is the role of non-polyQ containing domain in forming the initial interactions, thus suggesting a mechanism where these domains initially self-associate, thus increasing the local concentration of the polyQ tract before the polyQ tract plays a significant role in fibril formation. As additional polyQ disease proteins are characterized in vitro, it will be interestingly to observe whether this emerging trend continues.
The interplay between the polyQ domain and the stability of adjacent regions
The interplay between the polyQ tract and flanking domains clearly depends upon the characteristics of the domains. The stability of the flanking domain is known to play an important modulatory role in aggregation. In accordance with the general amyloid aggregation theory, an early hypothesis proposed that the expanded polyQ tract destabilized the protein, leading to an increased propensity to aggregate (Bevivino and Loll, 2001) . Ataxin-3 is the only disease protein for which kinetic and thermodynamic stability has been determined, and contrary to the initial hypothesis, our lab has shown that the addition of a non-pathogenic length polyQ tract leads to a destabilization of the protein in comparison with the Josephin domain alone, yet expanding the polyQ tract into the pathogenic length has no further effect on stability (Chow et al., 2004a (Chow et al., , 2004b . As the aggregation kinetics of expanded ataxin-3 is accelerated in comparison with nonexpanded ataxin-3, this suggests that because there is no further global destabilization, the expanded polyQ tract is modulating local stability or conformational dynamics.
The complexity of the effect of the polyQ tract on protein stability is demonstrated by a number of polyQ model systems. On the one hand, the addition and subsequent expansion of a polyQ tract did not result in a change in the thermodynamic stability of a Staphylococcus aureus protein A domain (Robertson et al., 2008) . However, this domain is one of the most stable of the model proteins used, so it is unsurprising that the addition of a pathogenic length polyQ tract was not sufficient to disrupt the fold. The CRABP I domain has a similar stability to the Josephin domain of ataxin-3; however, the addition of a non-expanded polyQ tract does not impact upon stability, and it is only when the polyQ tract is expanded that there is a corresponding decrease in the stability of the protein. Furthermore, although in a GST-polyQ model, the stability was not determined, aggregation could only be induced above 50ºC, suggesting the stability and/or solubility of the GST domain overrides any effects of the polyQ tract at physiological temperatures (Masino et al., 2002) . Therefore, these model systems demonstrate the complexity of the relationship between the polyQ tract and the flanking domains and show that although in some situations, a polyQ tract can decrease the global stability of a protein, it is not necessary in order to induce aggregation.
Effects of flanking domains on aggregation of non-polyQ proteins
Multi-domain misfolding is not exclusive to polyQ proteins, being also seen in several other aggregating proteins such as the poly alanine ( polyA) protein Poly A Binding Protein Nuclear 1 (PABPN1) and the yeast prion protein Ure2p. Expansion of the polyA tract occurs at the N-terminal of PABPN1, with an increase from 10 to 17 alanines leading to disease. Similar to ataxin-1 and ataxin-3, aggregation still occurs in the absence of the homo-sequence domain, resulting in aggregates which are smaller and more numerous than full-length PABPN1 (Klein et al., 2008) . A second example, Ure2p, consists of a highly amyloidogenic unstructured N-terminal domain which is responsible for the prion phenotype, and a compactly folded C-terminal catalytic domain (Thual et al., 1999) . Dimerization of the protein occurs through the C-terminal domain, which is also able to aggregate independently, forming high molecular weight insoluble oligomers, which do not progress to fibrillar aggregates (Thual et al., 2001) . Interestingly, the presence of the amyloidogenic N-terminal domain has no impact upon the stability of the full-length protein (Thual et al., 2001) .
Conclusions
The aggregation pathways of polyQ proteins characterized to date have involved multiple domains. With the variation seen between polyQ diseases, it is unsurprising that their specific flanking domains, although not the primary cause of aggregation, have the ability to independently misfold and modulate the fibrillogenic mechanism within the context of the full-length protein in vitro. In these studies, the importance of using a number of complementary techniques to follow the multiple aggregation steps has been highlighted. The mechanism via which an expanded polyQ tract results in accelerated aggregation remains unknown, with no clear relationship between the effects of the expanded polyQ tract and global stability of the protein. Further investigation into polyQ protein dynamics and the effects of the expanded polyQ tract upon local stability will therefore be important for determining the early aggregation events.
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